W H J Kruit

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. ncbi request reprint [Viewpoint of the Dutch Melanoma Working Group regarding sentinel lymph node biopsy: prognostic but not therapeutic implications]
    W H J Kruit
    Erasmus MC Daniel den Hoed Oncologisch Centrum, afd Interne Oncologie, Postbus 5201, 3075 EA Rotterdam
    Ned Tijdschr Geneeskd 152:574-6. 2008
  2. doi request reprint Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma
    Wim H J Kruit
    Department of Internal Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Oncol 31:2413-20. 2013
  3. ncbi request reprint Effect of combination therapy with aminoglutethimide and hydrocortisone on prostate-specific antigen response in metastatic prostate cancer refractory to standard endocrine therapy
    W H J Kruit
    Department of Medical Oncology, Daniel den Hoed Cancer Center, Erasmus Medical Center, Rotterdam, The Netherlands
    Anticancer Drugs 15:843-7. 2004
  4. doi request reprint Plasma activity of prolyl endopeptidase in relation to psychopathology during immunotherapy with IFN-alpha in patients with renal cell carcinoma
    A R Van Gool
    Department of Psychiatry, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Interferon Cytokine Res 28:283-6. 2008
  5. ncbi request reprint Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Researc
    C J A Punt
    Department of Medical Oncology, St Radboud University Nijmegen Medical Center, P O Box 9101, 6500 HB Nijmegen, The Netherlands
    Eur J Cancer 42:2991-5. 2006
  6. ncbi request reprint Influence of pegylated interferon-alpha therapy on plasma levels of citrulline and arginine in melanoma patients
    D Fekkes
    Department of Neuroscience, Erasmus MC, The Netherlands
    Amino Acids 32:121-6. 2007
  7. ncbi request reprint Serum activity of prolyl endopeptidase, but not of dipeptidyl peptidase IV, is decreased by immunotherapy with IFN-alpha in high-risk melanoma patients
    A R Van Gool
    Department of Psychiatry, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Interferon Cytokine Res 24:411-5. 2004
  8. pmc Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer
    M E L van der Burg
    Department of Medical Oncology, Rotterdam Cancer Institute and University Hospital, Rotterdam, P O Box 5201, 3008 AE Rotterdam, The Netherlands
    Br J Cancer 86:19-25. 2002
  9. ncbi request reprint Adoptive immuno-gene therapy of cancer with single chain antibody [scFv(Ig)] gene modified T lymphocytes
    C H J Lamers
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Biol Regul Homeost Agents 18:134-40. 2004
  10. ncbi request reprint Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma
    T Kivela
    Ocular Oncology Service, Department of Ophthalmology, Helsinki University Central Hospital, Haartmaninkatu 4, PL 220, Finland
    Eur J Cancer 39:1115-20. 2003

Detail Information

Publications14

  1. ncbi request reprint [Viewpoint of the Dutch Melanoma Working Group regarding sentinel lymph node biopsy: prognostic but not therapeutic implications]
    W H J Kruit
    Erasmus MC Daniel den Hoed Oncologisch Centrum, afd Interne Oncologie, Postbus 5201, 3075 EA Rotterdam
    Ned Tijdschr Geneeskd 152:574-6. 2008
    ..2-3.5 mm. There is no evidence to suggest that the sentinel lymph node procedure is beneficial when the Breslow thickness is less than 1.2 mm or greater than 3.5 mm...
  2. doi request reprint Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma
    Wim H J Kruit
    Department of Internal Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Oncol 31:2413-20. 2013
    ..This randomized phase II trial evaluated two different immunostimulants combined with the MAGE-A3 protein to investigate whether a more robust and persistent immune response could be associated with increased clinical benefit...
  3. ncbi request reprint Effect of combination therapy with aminoglutethimide and hydrocortisone on prostate-specific antigen response in metastatic prostate cancer refractory to standard endocrine therapy
    W H J Kruit
    Department of Medical Oncology, Daniel den Hoed Cancer Center, Erasmus Medical Center, Rotterdam, The Netherlands
    Anticancer Drugs 15:843-7. 2004
    ..Therapy was well tolerated with mainly grade I and II adverse events in 20% of patients. We conclude that aminoglutethimide is a valuable second-line therapy for patients with androgen-independent prostate cancer...
  4. doi request reprint Plasma activity of prolyl endopeptidase in relation to psychopathology during immunotherapy with IFN-alpha in patients with renal cell carcinoma
    A R Van Gool
    Department of Psychiatry, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Interferon Cytokine Res 28:283-6. 2008
    ..As more subtle relationships between PEP activity and psychiatric status could have easily been obscured, a role for PEP in the pathophysiology of IFN-alpha-induced mood disturbance can neither be confirmed nor excluded...
  5. ncbi request reprint Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Researc
    C J A Punt
    Department of Medical Oncology, St Radboud University Nijmegen Medical Center, P O Box 9101, 6500 HB Nijmegen, The Netherlands
    Eur J Cancer 42:2991-5. 2006
    ..This randomised phase II study was performed with the primary objective of exploring whether two cycles of dacarbazine monotherapy could select the subset of patients that would benefit most from more intensive chemoimmunotherapy...
  6. ncbi request reprint Influence of pegylated interferon-alpha therapy on plasma levels of citrulline and arginine in melanoma patients
    D Fekkes
    Department of Neuroscience, Erasmus MC, The Netherlands
    Amino Acids 32:121-6. 2007
    ..The data suggest that therapy with PEG-IFN-alpha results in a marked decrease in the synthesis of NO in melanoma patients...
  7. ncbi request reprint Serum activity of prolyl endopeptidase, but not of dipeptidyl peptidase IV, is decreased by immunotherapy with IFN-alpha in high-risk melanoma patients
    A R Van Gool
    Department of Psychiatry, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Interferon Cytokine Res 24:411-5. 2004
    ..In contrast, serum activity of DPP-IV did not change. Further studies focusing on a possible role of PEP in the pathophysiology of IFN-alpha-induced depression are warranted...
  8. pmc Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer
    M E L van der Burg
    Department of Medical Oncology, Rotterdam Cancer Institute and University Hospital, Rotterdam, P O Box 5201, 3008 AE Rotterdam, The Netherlands
    Br J Cancer 86:19-25. 2002
    ....
  9. ncbi request reprint Adoptive immuno-gene therapy of cancer with single chain antibody [scFv(Ig)] gene modified T lymphocytes
    C H J Lamers
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Biol Regul Homeost Agents 18:134-40. 2004
    ..Currently, we evaluate this concept in a clinical protocol to treat patients with metastatic renal cell cancer (RCC) using autologous RCC-specific gene-modified T lymphocytes...
  10. ncbi request reprint Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma
    T Kivela
    Ocular Oncology Service, Department of Ophthalmology, Helsinki University Central Hospital, Haartmaninkatu 4, PL 220, Finland
    Eur J Cancer 39:1115-20. 2003
    ..This multicentre study did not confirm earlier reports that BOLD with human leucocyte or recombinant interferon would induce at least 15% objective responses in metastatic uveal melanoma...
  11. ncbi request reprint [Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus]
    P H M de Mulder
    Universitair Medisch Centrum St Radboud, Nijmegen
    Ned Tijdschr Geneeskd 152:371-5. 2008
    ..These angiogenesis inhibitors did not receive mention in the recently published guideline 'Renal cell carcinoma'...
  12. ncbi request reprint Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report
    M Marchand
    Ludwig Institute for Cancer Research, Brussels Branch, Brussels, Belgium
    Eur J Cancer 39:70-7. 2003
    ..None of the tumour responses described above involved visceral metastases. Immunological responses to the vaccine will be reported separately...
  13. ncbi request reprint Regulation of ferritin: a specific role for interferon-alpha (IFN-alpha)? The acute phase response in patients treated with IFN-alpha-2b
    T C Stam
    Department of Surgical Oncology, University Hospital Rotterdam, Daniel den Hoed Cancer Centre, 3008 AE Rotterdam, The Netherlands
    Eur J Clin Invest 32:79-83. 2002
    ..To test this hypothesis, we studied ferritin and other APP levels in patients treated with IFN-alpha...
  14. ncbi request reprint [Guideline 'Melanoma' (3rd revision)]
    J J E van Everdingen
    Kwaliteitsinstituut voor de Gezondheidszorg CBO, Postbus 20 064, 3502 LB Utrecht
    Ned Tijdschr Geneeskd 149:1839-43. 2005
    ..There is no evidence to suggest that survival is improved by frequent follow-up. However, follow-up can be a useful way to meet the information needs of patients and care requirements for physicians...